Dutch company to develop diagnostic for Pfizer cancer drug

Monday 8 February 2010

The Netherlands-based diagnostics company, Qiagen NV, has reached an agreement with Pfizer Inc to develop a companion diagnostic for its immunotherapy vaccine, which is currently in Phase 2 development.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands